Investor Presentaiton

Investor presentation ADA 2019 Slide 19 In Dual VIII, mean HbA1c was comparable for XultophyⓇ compared with glargine U100 but with a lower actual insulin dose Mean change in HbA1c (%-point) IDegLira glargine U100 Actual daily Actual daily insulin dose (U) IDegLira glargine U100 Mean change in total insulin HbA1c (%) dose (U) 9.0 60 51 U 8.5 50 8.0 40 36 U 7.5 30 7.0 20 6.5% 6.5 10 6.4% 6.0 + 0 + + 04 12 26 38 52 0 12 26 38 52 64 78 90 104 64 78 90 104 Weeks Weeks At week 104, 90 patients (27.36%) had max dose of IDegLira. 75.3% were at target <7%; IDegLira/XultophyⓇ: insulin degludec/liraglutide; glargine U100: insulin glargine U100 novo nordisk

View entire presentation